

Commercial/Healthcare Exchange PA Criteria
Effective: July 1, 2017

Prior Authorization: Cambia

Products Affected: Cambia (diclofenac potassium) for oral solution

Medication Description: Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) of the acetic acid chemical class. The mechanism of action of Cambia, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2) and potent inhibition of prostaglandin synthesis.

Covered Uses: Acute treatment of migraine attacks with or without aura in adults 18 years of age or older

Exclusion Criteria:

1. Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac
2. History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs
3. In the setting of coronary artery bypass graft (CABG) surgery
4. Cambia is being used as a prophylactic therapy of migraine
5. Cambia is being used for cluster headaches

Required Medical Information:

1. Diagnosis
2. Previous medications tried/failed

Age Restrictions: 18 years of age and older

Prescriber Restrictions: N/A

Coverage Duration: 12 months

Other Criteria:

1. Patient has clinically diagnosed migraine headache; **AND**
2. Patient has a documented intolerance to, or treatment failure of, an adequate trial of **TWO** generic prescription strength non-steroidal anti-inflammatory drugs (naproxen, diclofenac, ibuprofen, meloxicam); **AND**
3. Patient has a documented intolerance to, or treatment failure of, an adequate trial of **TWO** generic “triptan” medications (sumatriptan, rizatriptan, eletriptan, naratriptan, almotriptan, frovatriptan, etc.).

References:

1. Cambia full prescribing information. Nautilus Neurosciences, Bedminster, NJ
2. Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, Co. 2019

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	07/01/2017
2	Update	<p>CCI adopted EH Policy, removed from CCI Cambia- Treximet Policy</p> <p>CCI P&T Review History: 9/10, 12/11, 10/12, 10/13, 10/14, 11/15, 11/16, 5/17, 5/18, 7/18, 5/19</p> <p>CCI Revision Record: 1/11, 11/16, 5/18, 7/18</p>	All	12/27/2019

